Загрузка...
Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
INTRODUCTION: BAY 81‐8973 (Kovaltry(®)) is a full‐length, unmodified recombinant human factor VIII approved in China for prophylaxis and on‐demand treatment in patients with haemophilia A. Limited access to FVIII prophylaxis in China has historically led to this population being undertreated. This s...
Сохранить в:
| Опубликовано в: : | Haemophilia |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6850381/ https://ncbi.nlm.nih.gov/pubmed/30993836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13751 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|